BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

Myeloma

Genomic Testing

Targeted Oncology's Pivotal Practice Views with the Oncology Brothers is a video series that focuses on recently-approved, practice-changing treatment options across tumor types.

1rem

Rahul Gosain, MD, MBA; Rohit Gosain, MD; and Anwaar Saeed, MD, evaluate the RATIONALE-305 and RATIONALE-306 trials, investigating tislelizumab and examining the trials’ key end points, including overall survival, progression-free survival, and safety outcomes.

FDA Approval of Tislelizumab

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its potential to improve patient convenience and treatment adherence while maintaining efficacy in the treatment of melanoma.

FDA Approval of Subcutaneous Nivolumab 

Along with the Oncology Brothers, Paolo Tarantino, MD, discuss the phase 3 EMERALD study of elacestrant versus standard-of-care endocrine therapy for estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC). Their conversation focuses on the implications of recently published data demonstrating that elacestrant provides a PFS benefit across clinically meaningful subgroups of patients with 

m), ER+, HER2- MBC, including those with endocrine-sensitive disease.

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. 

https://doi.org/10.1158/1078-0432.CCR-24-1073

Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups

Panelists discuss how the FDA approval of durvalumab, based on the AEGEAN trial, represents a significant advancement in treatment options, potentially improving patient outcomes in clinical practice.

FDA Approval of Durvalumab (AEGEAN Trial)

Panelists discuss various stages of graft-vs-host disease (GVHD) and chronic GVHD (cGVHD), and the study of axatilimab as a treatment within the AGAVE-201 study.

FDA Approval of Axatilimab (Phase 2 AGAVE-201)

Arvind Dasari, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers, to discuss the FRESCO-2 data and its impact on the colorectal cancer landscape.

FRESCO-2: Fruquintinib

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.

EV-302: Enfortumab Vedotin and Pembrolizumab

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the FDA approval of zanubrutinib and where it fits in clinical practice, highlighting data from the ALPINE and SEQUOIA studies.

FDA Approval of Zanubrutinib (ALPINE & SEQUOIA Study)

Hope Rugo, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss data from CAPItello-291 on capivasertib and how it has changed the treatment landscape in HR+ breast cancer.

Updates in HR+ Breast Cancer Treatment: Expert Perspectives on CAPItello-291

Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Jonathan Friedberg, MD, MMSc, in their review of respective data from POLARIX in DLBCL and SWOG S1826 in Hodgkin’s Lymphoma.

Updates in Frontline Therapy for Lymphoma: Perspectives on the POLARIX and SWOG S1826 Clinical Trials

The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Jonathan E. Rosenberg, MD, to discuss recent data from a phase 2 study investigating enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic bladder cancer.

Key Data From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers to review data from the EMERALD trial and discuss use of the oral SERD, elacestrant, in patients with ER+, HER2- advanced breast cancer.

Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer